Find News

Filter articles

Applied Filters

Showing 971 to 980 of 1058 results

US Supreme Court agrees to hear Copaxone appeal

India, Israel, US01-04-2014Legal developments

The US Supreme Court has agreed to hear Teva’s appeal against a Federal Circuit decision that invalidated a patent covering its $4.3 billion-a-year Copaxone (glatiramer acetate) drug, allowing Sandoz, Mylan and Natco to produce generic versions.

Novartis launches Gleevec action against Dr. Reddy’s

US28-03-2014Legal developments

Novartis has sued generic drugmaker Dr. Reddy’s Laboratories for infringing a patent related to its chronic myelogenous leukaemia drug Gleevec/Glivec (imatinib mesylate).

Mylan fights off Teva’s Perforomist challenge

US25-03-2014Legal developments

The US District Court for the Northern District of West Virginia has upheld the validity of four patents covering Mylan’s Perforomist (formoterol fumarate) inhalation solution.

Cephalon sues to protect cancer drug Treanda

US19-03-2014Legal developments

Teva-owned subsidiary Cephalon has sued Sun Pharma, claiming the Mumbai-based firm infringed a patent protecting its Treanda (bendamustine hydrochloride) product.

Pfizer sues to block Viagra generic

US18-03-2014Legal developments

Pfizer has filed patent infringement suits against India-based Torrent Pharmaceuticals in an attempt to stop it selling a generic version of erectile dysfunction drug Viagra (sildenafil citrate).

Eli Lilly targets more than 30 generics in Effient patent case

US17-03-2014Legal developments

Eli Lilly has filed suit against more than 30 generic drug makers at the US District Court for the Southern District of Indiana for allegedly infringing three patents related to platelet inhibitor drug Effient (prasugrel).

Generics circle as Virginia court invalidates Celebrex patent

US13-03-2014Legal developments

The US District Court for the Eastern District of Virginia has invalidated one of Pfizer’s patents covering blockbuster arthritis drug Celebrex.

Life Sciences Law Forum: UPC: “So much more to be done”


While the political will exists for the introduction of the Unified Patent Court next year, much more still needs to be done, according to Adam Cooke, a partner in DLA Piper's IP and technology group.

Indian court dismisses Teva’s bid to block Copaxone generic


The Delhi High Court has dismissed Teva’s action to stop Hyderabad-based Natco Pharma from marketing a generic version of its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).

Federal Circuit rejects challenge to GSK’s Avodart and Jalyn

US28-02-2014Legal developments

The US Appeals Court for the Federal Circuit has affirmed a lower court decision that GlaxoSmithKline’s patent covering Avodart and Jalyn is valid, rejecting claims put forward by a group of generic drug makers.

Showing 971 to 980 of 1058 results